We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Phathom Pharmaceuticals Inc
2 own
4 watching
Current Price
$6.9
$-0.27
(-3.77%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
517.51M
52-Week High
19.71000
52-Week Low
6.065000
Average Volume
1.16M
Dividend Yield
--
P/E Ratio
--
Market Capitalization517.51M52-Week High19.7100052-Week Low6.065000Average Volume1.16MDividend Yield--P/E Ratio--What does the Phathom Pharmaceuticals Inc do?
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Read More
How much money does Phathom Pharmaceuticals Inc make?
News & Events about Phathom Pharmaceuticals Inc.
Globe Newswire
1 year ago
NEW YORK, June 19, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Integra LifeSciences Holdings Corp. (NASDAQ: IART), Chinook Therapeutics, Inc. (NASDAQ: KDNY), Phathom Pharmaceuticals, Inc. (NASDAQ...
Globe Newswire
1 year ago
Prescription Drug User Fee Act (PDUFA) goal date of November 17, 2023Combined launch of vonoprazan for Erosive GERD and H. pylori indications planned for Q4 2023, if approved FLORHAM PARK, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical ...
PR Newswire
1 year ago
PHAT FRAUD ALERT: Jakubowitz Law is Investigating Phathom Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws PHAT FRAUD ALERT: Jakubowitz Law is Investigating Phathom Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws PR...
Ticker Report
1 year ago
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT Get Rating) COO Azmi Nabulsi acquired 10,000 shares of the businesss stock in a transaction that occurred on Tuesday, April 11th. The stock was bought at an average cost of $8.26 per share, for a total transaction of $82,600.00. Following the...
Zolmax
1 year ago
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT Get Rating) COO Azmi Nabulsi acquired 10,000 shares of the businesss stock in a transaction that occurred on Tuesday, April 11th. The stock was bought at an average cost of $8.26 per share, for a total transaction of $82,600.00. Following the completion of ...
Frequently Asked Questions
Frequently Asked Questions
What is Phathom Pharmaceuticals Inc share price today?
Can Indians buy Phathom Pharmaceuticals Inc shares?
How can I buy Phathom Pharmaceuticals Inc shares from India?
Can Fractional shares of Phathom Pharmaceuticals Inc be purchased?
What are the documents required to start investing in Phathom Pharmaceuticals Inc stocks?
What is today’s traded volume of Phathom Pharmaceuticals Inc?
What is today’s market capitalisation of Phathom Pharmaceuticals Inc?
What is the 52-Week High and Low Range of Phathom Pharmaceuticals Inc?
What percentage is Phathom Pharmaceuticals Inc down from its 52-Week High?
What percentage is Phathom Pharmaceuticals Inc up from its 52-Week Low?
Current Price
$6.9
$-0.27
(-3.77%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.